Practical Insights into Lactose-Based DPI Formulations

Three prominent industry leaders with complementary expertise—lactose specialist DFE Pharma, powder processing technology manufacturer Hosokawa Micron and machine-building expert Harro Hoefliger, which is specialized in pharmaceutical and medical devices and in particular capsule filling machines—collaborated on a comprehensive study exploring the formulation of dry powder inhalers (DPIs) that incorporate magnesium stearate-coated lactose.

With this multidisciplinary approach, the companies aim to generate practical insights for pharmaceutical players, particularly those involved in asthma and COPD treatment. This joint effort builds on their expertise in lactose, powder processing technology, and capsule-filling machinery, ultimately supporting the development of more efficient DPI formulations.

The Evolving DPI Market and Formulation Challenges

Lactose-based DPI formulations are widely used in inhaled therapies, but the industry has increasingly focused on enhancing these mixtures by incorporating magnesium stearate. This addition creates ternary blends of lactose, active pharmaceutical ingredients (APIs), and magnesium stearate, which improve flow properties and dosage uniformity. However, the intricate interactions between components in these formulations present significant challenges, as slight changes can impact the overall efficacy of drug delivery to the lungs.

Many pharmaceutical companies are eager to develop their own DPI products, yet lack comprehensive insights into how each formulation component—such as lactose quality, particle size distribution, and blending techniques—affects the final product. The research conducted by DFE Pharma, Hosokawa Micron, and Harro Hoefliger addresses questions like the optimal blend of coarse and fine lactose, the impact of magnesium stearate, and the effects of various blending and filling parameters on formulation stability.

Multidisciplinary Study for Enhanced Data and Insights

The joint research project emerged from the companies’ shared interest in providing data-driven support to their clients, helping them to overcome the inherent complexities of DPI formulations. Over the course of the year-long study, a team comprising specialists from each company performed trials to investigate how different parameters influence powder behavior during production and dosing.

In these trials, DFE Pharma supplied varying grades and concentrations of fine lactose to Hosokawa Micron, which blended the lactose with and without magnesium stearate to establish baseline cohesiveness and stickiness levels. The coated blends were then delivered to Harro Hoefliger, where the team examined the impact on capsule filling and dosing, exploring how different lactose qualities and magnesium stearate concentrations influenced the process.

Data-Driven Findings to Support Faster Development

The research revealed that adding magnesium stearate significantly affects the flowability of the lactose-based powders. Through extensive testing and analysis, the team quantified critical thresholds, such as permeability and compressibility, that influence formulation consistency. This knowledge is invaluable to pharmaceutical manufacturers seeking low relative standard deviation (RSD) in DPI production—critical for dosage precision and efficiency.

The team’s analysis includes insights into mixing and filling techniques, exploring technologies like drum fillers and dosators. By identifying optimal parameters, the study provides clients with actionable data, enabling them to streamline their development processes, reduce waste, and shorten time-to-market.

Final Phase and Future Application

In the study’s concluding phase, the team tested the full formulation, including APIs, using DFE Pharma’s lactose and Hosokawa’s mixing technology. Conducted at Harro Hoefliger’s facility, this phase focused on high-shear blending and comprehensive evaluations of flow properties, blend uniformity, and dose consistency. Testing parameters such as emitted dose and aerodynamic particle size distribution (APSD), combined with short-term stability studies, aimed to validate the formulation’s performance in real-world applications.

These findings underscore the benefits of a collaborative approach, providing pharmaceutical companies with guidance to fine-tune their DPI formulations, potentially avoiding the need for costly adaptations to blending and filling equipment.

Industry Collaboration for Progress

With this unique study, DFE Pharma, Hosokawa Micron, and Harro Hoefliger have created a foundation for knowledge-sharing across the pharmaceutical sector. Their findings not only assist generic players in optimizing DPI formulations but also foster a deeper understanding of the interactions between lactose, magnesium stearate, and APIs. This knowledge will contribute to more predictable, efficient development processes for DPI products, benefiting both manufacturers and patients alike.

A Total Solution for the Pharmaceutical Market

Bert Dekens of Hosokawa Micron emphasized the benefits of an integrated ecosystem: “Our combined expertise allows us to offer customers a total solution, extending beyond traditional boundaries to provide comprehensive support.” Marco Laackmann from Harro Hoefliger added that the research “strengthens our understanding of the coating process and its impact on formulation consistency.” Harry Peters from DFE Pharma highlighted the value of early-stage collaboration, noting that “by engaging in dialogue early in development, we can help customers align their formulations with existing equipment, saving valuable time and resources.”

This study exemplifies how a well-coordinated approach can yield substantial advancements in DPI formulation technology, offering practical solutions for an increasingly complex market.

Click here to get directed to the website dedicated to the study